AstraZeneca announced that three of its cancer compounds—moxetumomab pasudotox, olaparib and selumetinib—will be moving forward to Phase III clinical development. Oncology is one of the company's c...
new molecular entities in our late-stage pipeline 3 new molecular entities under review Phase III/LCM Projects: refers to assets that are pivotal in Phase II/III, or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets (...
Oncology R&D, said: “Our data at AACR reflect a robust early-stage pipeline, poised to deliver life-changing medicines to patients living with cancer. Data for AZD5305 will demonstrate how the next wave of DNA damage response medicines can build on the success ...
AstraZeneca, home of cancer blockbusters like Tagrisso and Daiichi Sankyo-partnered Enhertu, wants to elevate its cancer pipeline and is sharing a peek at data from three bispecific antibody candidates at this year's European Society for Medical Oncology (ESMO) Congress. The Big Pharma’s “2.0...
AstraZenecais strengthening its oncology pipeline with theacquisitionof TeneoTwo, which has an ongoing Phase I trial in relapsed and refractory B-cell non-Hodgkin lymphoma, in a deal valued at up to $1.27 billion. The transaction, expected to close in the third quarter of this year, includes...
AstraZeneca showcases strength of hematology portfolio and pipeline at ASH 2024 7 November 2024 AIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA ...
AstraZeneca showcases strength of hematology portfolio and pipeline at ASH 2024 7 November 2024 AIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA ...
AstraZeneca will share updates from the company’s innovative early oncology pipeline across multiple strategic platforms during the virtual American Association of Cancer Research (AACR) Annual Meeting, 10 to 15 April 2021. Five presentations will unveil the next-generation PARP1 selective inhibitor AZD...
AstraZeneca is focused on strengthening its oncology business strengthening its oncology product portfolio through label expansions of existing products and progressing oncology pipeline candidates. Oncology sales now comprise around 40% of AstraZeneca‘s total revenues and rose 17% in 2021, 19% in 2022...
Anas Younes, Senior Vice President, Oncology R&D, AstraZeneca, said: “At this year’s ASH Annual Meeting, our data demonstrate the broad potential of our hematology pipeline and the continued strength of our approved medicines. Data are being highlighted from many of our early-s...